• Explore /
  • Poster
  • / Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Celestia Higano

Celestia S. Higano

Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA

Celestia S. Higano , Fred Saad , A. Oliver Sartor , Kurt Miller , Peter Conti , Daniel J. George , Cora N. Sternberg , Neal D. Shore , Juan Pablo Sade , Joaquim Bellmunt , Matthew Raymond Smith , Christopher Logothetis , Frank Verholen , Jan Kalinovsky , Inga Bayh , Bertrand F. TOMBAL

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT02141438

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 32)

Abstract #

32

Poster Bd #

A20

Abstract Disclosures

Similar Posters

First Author: Lauren Christine Harshman

First Author: Nicholas D. James

First Author: Celestia S. Higano

First Author: A. Oliver Sartor